Abstract
BACKGROUND
Colorectal cancer (CRC) screening can be administered through tests with varied characteristics and is a preference-sensitive decision.
OBJECTIVE
To assess patient experiences with a Maximum Differences Scaling (MDS) tool for eliciting values about CRC screening test characteristics and determine whether patients vary in how they prioritize test characteristics and whether this variation relates to test preferences.
DESIGN
MDS survey to elicit patients’ values for characteristics related to fecal occult blood testing, sigmoidoscopy, colonoscopy, CT colonography and colon capsule endoscopy.
PARTICIPANTS
92 patients enrolled in primary care clinics at a VA hospital and associated university.
RESULTS
Patients reported that the tool was easy to use (95%). On completion 62% would choose colonoscopy, 23% colon capsule endoscopy and 10% CT colonography. Of the attributes evaluated, patients valued sensitivity, risk of tear and need for a second test most. Sensitivity was more important to those choosing colonoscopy than those choosing other tests (median importance = 21.5 versus 19.6, p < 0.01). Concern with complications and sedation was positively associated with age (p < 0.001 and p < 0.001), whereas concern with colon preparation and missing work was negatively associated with age (p < 0.009 and p < 0.03). Patients with fair or poor health status were less concerned with sensitivity than patients in good to excellent health (median importance = 19.3 versus 21.4, p < 0.008).
CONCLUSIONS
This pilot study suggests that patients vary in how they prioritize colorectal cancer screening test attributes; this variation is associated with test preferences, and this MDS tool is feasible to use and may help patients construct their preferences.
Similar content being viewed by others
References
Beauchamp T, Childress J. Principles of Biomedical Ethics. New York: Oxford University Press; 1983.
Allicock M, Sandelowski M, DeVellis B, Campbell M. Variations in meanings of the personal core value "Health". Patient Educ Counsel. 2008;73:347–53.
Reyna V. A theory of medical decision making and health: fuzzy trace theory. Med Decis Making. 2008;28:850–65.
Mandel J, Bond J, Church T, for the Minnesota colon cancer control study, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–71.
Kronborg O, Fenger C, Olsen J, Jorgensen O, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71.
Hardcastle J, Chamberlain J, Robinson M, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.
Winawer S, Zauber A, Ho M, The National Polyp Study Group, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329:1977–81.
Newcomb P, Norfleet R, Storer B, Surawicz T, Marcus P. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst. 1992;84:1572–5.
Muller A, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. Arch Intern Med. 1995;155:1741–48.
Selby J, Friedman G, Quesenberry C, Weiss N. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653–7.
SEER Stat Fact Sheet; colon and rectum. National Cancer Institute. Available at: http://seercancergov/statfacts/html/colorecthtml Accessed June 3, 2009.
Jemal A, Siegal R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.
Eliakim R, Fireman Z, Gralnek I, et al. Evaluation of the PillCam™ Colon capsule in the detection of colonic pathology: results of the first multicenter, prospective, comparative study. Endoscopy. 2006;38:963–70.
Schoofs N, Deviere J, Van Gossun A. PillCam™ colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. Endoscopy. 2006;38:971–7.
Pignone M, Bucholtz D, Harris R. Patient preferences for colon cancer screening. J Gen Intern Med. 1999;14:432–7.
Pignone M. Patient preferences for colon cancer screening: the role of out-of-pocket costs. Am J Managed Care. 2007;13:390–92.
Schroy P, Lal S, Glick J, Robinson P, Zamor P, Heerem T. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Managed Care. 2007;13:393–400.
Pignone M, Harris R, Kinsinger L. Videotape-based decision aid for colon cancer screening. A randomized, controlled trial. Ann Intern Med. 2000;133:761–69.
Dolan N, Frisina S. Randomized controlled trial of a patient decision aid for colorectal cancer screening. Med Decis Making. 2002;22:125–39.
Griffith J, Lewis C, Brenner A, Pignone M. The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial. BMC Med Inform and Decis Making. 2008;8:4–9.
Griffith J, Fichter M, Fowler F, Lewis C, Pignone M. Should a colon cancer screening decision aid include the option of no testing? A comparative trial of two decision aids. BMC Med Inform and Decis Making. 2008;8:10–9.
Kim J, Whitney A, Hayter S, et al. Development and initial testing of a computer-based patient decision aid to promote colorectal cancer screening for primary care practice. BMC Med Inform and Decis Making. 2005;5:36–47.
Ruffin M, Fetters P, Jimbo M. Preference-based electronic decision aid to promote colorectal cancer screening: Results of a randomized controlled trial. Prevent Med. 2007;45:267–73.
Van Dam L, Hol L, Bekker-Grob E, et al. What determines individuals’ preferences for colorectal cancer screening programmes? A discrete choice experiment. Eur J Cancer 2009;(2009). doi:10.1016/j.ejca.2009.07.014.
Hawley S, Volk R, Krishnamurthy P, Jibaja-Weiss M, Vernon S, Kneuper S. Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients. Med Care. 2008;46:S10–6.
Marshall D, Johnson F, Phillips K, Marshall J, Thabane L, Kulin N. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health. 2007;10:415–30.
Dolan J. Patient priorities in colorectal cancer screening decisions. Health Expect. 2005;8:334–44.
U.S Preventative Services Task Force USPST. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–37.
Louviere, J. The best-worst or maximum difference measurement model: Applications to behavioral research in marketing. The American Marketing Association's Behavioral Research Conference Phoenix, Arizona 1993.
Flynn T, Louviere J, Peters T, Coast J. Estimating preferences for a dermatology consultation using Best-Worst Scaling: comparison of various methods of analysis. BMC Med Res Methodol. 2008;8:76–88.
Understanding HB: An intuitive approach. Richard M. Johnson, Sawtooth Software. 2000. Available at: http://www.sawtoothsoftware.com/download/techpap/undhb.pdf Accessed October 5, 2009.
MaxDiff analysis: simple counting, individual-level logit, and HB. Bryan Orme. Sawtooth Software, Inc. Available at: http://www.sawtoothsoftware.com/download/techpap/inivmaxdiff.pdf Accessed October 5, 2009.
Fraenkel, L., Chodkowski, D., Lim, J., Garcia-Tsao, G. Patients’ preferences for treatment of hepatitis C. Med Decis Making 2009. doi:10.1177/0272989X09341588.
Fraenkel L, Bogardus S, Concato J, Felson D, Wittink D. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis. 2004;63:1372–8.
Longacre A, Imaeda A, Garcia-Tsao G, Fraenkel L. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage. Hepatology. 2008;47:169–76.
DeBourcy A, Lichtenberger S, Felton S, Butterfield K, Ahnen D, Denberg T. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med. 2007;23:169–74.
Almog R, Ezra G, Lavi I, Rennert G, Hagoel L. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening. Eur J Cancer Prevent. 2008;17:430–37.
Ling B, Moskowitz M, Wachs D, Pearson B, Schroy P. Attitudes toward colorectal cancer screening tests. A survey of patients and physicians. J Gen Intern Med. 2001;16:822–30.
Leard L, Savides T, Ganiats T. Patient preferences for colorectal cancer screening. J Fam Pract. 1997;45:211–18.
Nelson R, Schwartz A. A survey of individual preference for colorectal cancer screening technique. BMC Cancer. 2004;4:76.
Wolf R, Basch C, Brouse C, Shmuckler C, Shea S. Patient preferences and adherence to colorectal cancer screening in an urban population. Am J Public Health. 2006;96:809–11.
Powell A, Burgess A, Vernon S, et al. Colorectal cancer screening mode preferences among US veterans. Prevent Med. 2009;49:442–48.
McGregor E, Hilsden R, Li F, Bryant H, Murray A. Low uptake of colorectal cancer screening 3 years after release of national recommendations for screening. Am J Gastro. 2007;102:1727–35.
Meissner H, Breen N, Klabunde C, Vernon S. Patterns of colorectal cancer screening uptake among men and woman in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15:389–94.
Acknowledgements
Dr. Fraenkel is supported by the K23 Award AR048826-01 A1
Conflict of Interest
None disclosed.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented in abstract form at Digestive Diseases Weekly June 2009, Chicago, IL.
Electronic Supplementary Materials
Below is the link to the electronic supplementary material.
Supplementary material
(PDF 82 kb)
Rights and permissions
About this article
Cite this article
Imaeda, A., Bender, D. & Fraenkel, L. What Is Most Important to Patients when Deciding about Colorectal Screening?. J GEN INTERN MED 25, 688–693 (2010). https://doi.org/10.1007/s11606-010-1318-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-010-1318-9